secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001104659-24-068055
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia updates corporate presentation; MicroPine interim readout 4Q 2024, Clobetasol launch 3Q 2024
--------------------------------------------------------------------------------

- MicroPine Phase 3 CHAPERONE interim DMC review expected 4Q 2024; SAE rate <1 per 1,000 patient-months, all unrelated.
- Clobetasol propionate 0.05% launch expected 3Q 2024; projected 3rd-year sales $50M; co-promotion with NovaBay for Avenova.
- Optejet Gen-2 FDA meeting planned 3Q 2024 to confirm pathway for drug/device; licensing targets dry eye and glaucoma (>$8.8B market).
- MicroPine potential peak US sales >$1B by 2036; net price $200/month, COGS <$20; addresses ~5M high-risk myopic children.
- Optecare digital compliance system built into Optejet to track adherence; aims to improve patient outcomes and differentiate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924068055/0001104659-24-068055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924068055/tm2416348d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-068055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer